| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | BRD-K51490254 | CTRPv2 | pan-cancer | AAC | -0.0059 | 0.9 |
| mRNA | BIX02189 | GDSC1000 | pan-cancer | AAC | 0.0049 | 0.9 |
| mRNA | SB 216763 | GDSC1000 | pan-cancer | AAC | -0.0059 | 0.9 |
| mRNA | alvocidib | CTRPv2 | pan-cancer | AAC | 0.0083 | 0.9 |
| mRNA | Bortezomib | gCSI | pan-cancer | AAC | -0.0088 | 0.9 |
| mRNA | ruxolitinib | GDSC1000 | pan-cancer | AAC | 0.0051 | 0.9 |
| mRNA | PLX4720 | GDSC1000 | pan-cancer | AAC | -0.0046 | 0.9 |
| mRNA | Cytarabine | CTRPv2 | pan-cancer | AAC | 0.0043 | 0.9 |
| mRNA | COL-3 | CTRPv2 | pan-cancer | AAC | 0.006 | 0.9 |
| mRNA | navitoclax:sorafenib (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.0052 | 0.9 |